var data={"title":"Acetaminophen (paracetamol) and tramadol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Acetaminophen (paracetamol) and tramadol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7081?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=acetaminophen-paracetamol-and-tramadol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Acetaminophen (paracetamol) and tramadol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46307072\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada, in collaboration with manufacturers, will update the Canadian labelling of all prescription opioid products to include the following:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation for a daily opioid threshold dose for the management of chronic noncancer, nonpalliative pain (which aims to reduce risks of adverse events and overdoses associated with higher doses of opioids);</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation to limit the quantity of opioids prescribed for acute pain (which aims to reduce the duration of use and associated risks of developing dependence and substance use disorder); and</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Clarification of warnings, including those for special populations such as pregnant women and patients with a history of dependence or substance use disorder.</p></li></ul>\n        <p style=\"text-indent:0em;\">Health Canada has prioritized product tables for updating based on risk. The labelling updates for all prescription opioids are expected to be completed in January 2019.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65362a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13114310\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Addiction, abuse, and misuse:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Tramadol/acetaminophen exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient&rsquo;s risk prior to prescribing tramadol/acetaminophen, and monitor all patients regularly for the development of these behaviors and conditions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening respiratory depression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, life-threatening, or fatal respiratory depression may occur with use of tramadol. Monitor for respiratory depression, especially during initiation of tramadol/acetaminophen or following a dose increase.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Accidental ingestion:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Accidental ingestion of even one dose of tramadol/acetaminophen, especially by children, can result in a fatal overdose of tramadol.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ultra-rapid metabolism of tramadol and other risk factors for life-threatening respiratory depression in children</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Life-threatening respiratory depression and death have occurred in children who received tramadol. Some of the reported cases occurred following tonsillectomy and/or adenoidectomy; in at least 1 case, the child had evidence of being an ultra-rapid metabolizer of tramadol due to a CYP-450 2D6 polymorphism. Tramadol/acetaminophen is contraindicated in pediatric patients &lt;12 years and in pediatric patients &lt;18 years following tonsillectomy and/or adenoidectomy<i>. </i>Avoid the use of tramadol/acetaminophen in pediatric patients 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of tramadol.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonatal opioid withdrawal syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prolonged use of tramadol/acetaminophen during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cytochrome P450 interactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol/acetaminophen requires careful consideration of the effects on the parent drug, tramadol, and the active metabolite, M1.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4 g/day, and often involve more than one acetaminophen-containing product.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of tramadol/acetaminophen and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229717\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ultracet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1582162\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tramacet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229734\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic Combination (Opioid);</li>\n      <li>\n        Analgesic, Opioid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229719\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Pain management:</b> Oral: Acetaminophen 325 mg/tramadol 37.5 mg: Two tablets every 4 to 6 hours as needed for pain relief (maximum: 8 tablets/day [acetaminophen 2,600 mg/tramadol 300 mg per day]); do not exceed 5 days of therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229720\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229721\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: Maximum: Two tablets every 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229722\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use is not recommended (acetaminophen and tramadol undergo extensive hepatic metabolism).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229702\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ultracet: Acetaminophen 325 mg and tramadol hydrochloride 37.5 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Acetaminophen 325 mg and tramadol hydrochloride 37.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229687\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48842545\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tramacet: Acetaminophen 325 mg and tramadol hydrochloride 37.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708104\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49627716\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021123s014lbl.pdf#page=45&amp;token=Np1qoF4TyyYL6ls0lYni1oRrWAim8HRCHbjchVEWMpPrm8/17fPXzper/SMtd/D8vyniVLQq9HCOBh8kfJ48q54p1wWoiuVpDmz5TYmLW489jRgp2ZSL7D80cxKrfROq&amp;TOPIC_ID=9166\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021123s014lbl.pdf#page=45</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229703\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management:</b> Short-term (&le;5 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Reserve tramadol/acetaminophen for use in patients for whom alternative treatment options (eg, nonopioid analgesics) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5118567\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ultracet may be confused with Duricef, Ultane, Ultram</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229693\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Also see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (6%), dizziness (3%), insomnia (2%), anxiety, confusion, euphoria, fatigue, headache, nervousness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (4%), pruritus (2%), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (6%), anorexia (3%), diarrhea (3%), nausea (3%), xerostomia (2%), abdominal pain, dyspepsia, flatulence, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Prostatic disease (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormality in thinking, albuminuria, amnesia, anemia, ataxia, cardiac arrhythmia, changes in liver function, chest pain, convulsions, depersonalization, depression, drug abuse, dysphagia, dyspnea, emotional lability, exacerbation of migraine headache, exacerbation of hypertension, hallucination, hypertension, hypertonia, hypotension, impotence, melena, migraine, muscle spasm, nightmares, oliguria, palpitations, paresthesia, rigors, stupor, syncope, tachycardia, tinnitus, tongue edema, urinary retention, urination disorder, vertigo, visual disturbance, weight loss, withdrawal syndrome (with abrupt discontinuation; includes anxiety, diarrhea, hallucinations [rare], nausea, pain, piloerection, rigors, sweating, and tremor; uncommon discontinuation symptoms may include severe anxiety, panic attacks, or paresthesia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229706\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to acetaminophen, tramadol, or any component of the formulation; pediatric patients &lt;12 years; postoperative management in pediatric patients &lt;18 years who have undergone tonsillectomy and/or adenoidectomy; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; GI obstruction, including paralytic ileus (known or suspected); concomitant use with or within 14 days following MAO inhibitor therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for opioids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Known or suspected mechanical GI obstruction (eg, bowel obstruction, strictures) or any disease/condition that affects bowel transit; suspected surgical abdomen (eg, acute appendicitis, pancreatitis); severe renal impairment (creatinine clearance &lt;30 mL/minute); severe hepatic impairment (Child-Pugh class C); mild pain that can be managed with other pain medications; acute or severe bronchial asthma, chronic obstructive airway, or status asthmaticus; acute respiratory depression, hypercapnia, or cor pulmonale; acute alcoholism, delirium tremens, or seizure disorder; severe CNS depression, increased cerebrospinal or intracranial pressure, or head injury; any situation where opioids are contraindicated (eg, acute intoxication with alcohol, hypnotics, centrally acting analgesics, opioids or psychotropic drugs); breastfeeding; pregnancy; use during labor and delivery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229691\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Serious anaphylactoid reactions (including rare fatalities) often following initial dosing have been reported. Pruritus, hives, bronchospasm, angioedema, toxic epidermal necrolysis (TEN), and Stevens-Johnson syndrome have also been reported with use. Previous anaphylactoid reactions to opioids may increase risks for similar reactions to tramadol. If anaphylaxis or other hypersensitivity occurs, discontinue permanently; do not rechallenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed &gt;4 g/day, and often involve more than 1 acetaminophen-containing product.</b> Risk is increased with alcohol use, preexisting liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: <b>[US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely for respiratory depression, especially during initiation or dose increase.</b> Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Even when taken within the recommended dosage seizures may occur; risk is increased in patients receiving serotonin reuptake inhibitors (SSRIs or anorectics), other opioids, tricyclic antidepressants or other cyclic compounds (including cyclobenzaprine, promethazine), neuroleptics, MAO inhibitors, drugs which may lower seizure threshold, or drugs which impair metabolism of tramadol (ie, CYP2D6 and 3A4 inhibitors). Patients with a history of seizures, or with a risk of seizures (head trauma, metabolic disorders, CNS infection, malignancy, or during alcohol/drug withdrawal) are also at increased risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: May occur with concomitant use of serotonergic agents (eg, SSRIs, SNRIs, triptans, TCAs), lithium, St John&rsquo;s wort, agents that impair metabolism of serotonin (eg, MAO inhibitors), or agents that impair metabolism of tramadol (eg, CYP2D6 and 3A4 inhibitors). Monitor patients for serotonin syndrome such as mental status changes (eg, agitation, hallucinations, coma); autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia); neuromuscular changes (eg, hyperreflexia, incoordination); and/or GI symptoms (eg, nausea, vomiting, diarrhea).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: Rarely, acetaminophen may cause serious and potentially fatal skin reactions such as acute generalized exanthematous pustulosis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Discontinue treatment if severe skin reactions develop.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary tract impairment: Use caution in patients with biliary tract dysfunction or acute pancreatitis; opioids may cause spasm of the sphincter of Oddi.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression/coma: Avoid use in patients with impaired consciousness or coma as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delirium tremens: Use with caution in patients with delirium tremens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use is not recommended; acetaminophen and tramadol undergo extensive hepatic metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in patients who are morbidly obese.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Use with caution in patients with toxic psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicide risk: Avoid use in patients who are suicidal; use with caution in patients taking tranquilizers and/or antidepressants, or those with an emotional disturbance including depression. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzodiazepines or other CNS depressants: <b>[US Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of tramadol/acetaminophen and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosage and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP P450 interactions: <b>[US Boxed Warning]: The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol/acetaminophen requires careful consideration of the effects on the parent drug, tramadol, and the active metabolite, M1. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP2D6 &ldquo;ultrarapid metabolizers&rdquo;: Avoid use in patients who are ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications donated as *1/*1xN or *1/*2xN); these patients may have extensive conversion to morphine and thus increased opioid-mediated effects. The occurrence of this phenotype is seen in approximately 1% to 2% of East Asians (Chinese, Japanese, Korean), 1% to 10% of Caucasians, 3 to 4% of African-Americans, and may be &gt;10% in certain racial/ethnic groups (ie, Oceanian, Northern African, Middle Eastern, Ashkenazi Jews, Puerto Rican).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Clearance may be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increasing the risk for respiratory depression or overdose (Dowell [CDC 2016]). Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonatal withdrawal syndrome: <b>[US Boxed Warning]: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available</b>. Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. Onset, duration and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: <b>[US Boxed Warning]: </b><b>Life-threatening respiratory depression and death have occurred in children who received tramadol. Some of the reported cases occurred following tonsillectomy and/or adenoidectomy; in at least 1 case, the child had evidence of being an ultra-rapid metabolizer of tramadol due to a CYP-450 2D6 polymorphism. Tramadol/acetaminophen is contraindicated in pediatric patients &lt;12 years and in pediatric patients &lt;18 years following tonsillectomy and/or adenoidectomy<i>. </i>Avoid the use of tramadol/acetaminophen in pediatric patients 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of tramadol. </b>Risk factors include conditions associated with hypoventilation, such as postoperative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression. Deaths have also occurred in breastfeeding infants after being exposed to high concentrations of morphine because the mothers were ultra-rapid metabolizers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion: <b> [US Boxed Warning]: Use exposes patients and other users to the risks of addiction, abuse, and misuse, potentially leading to overdose and death. Assess each patient&rsquo;s risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions.</b> Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Other factors associated with increased risk for misuse include younger age, concomitant depression (major), and psychotropic medication use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental ingestion: <b>[US Boxed Warning]: Accidental ingestion of even one dose, especially in children, can result in a fatal overdose of tramadol.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dosage limit: Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated, the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Opioids decrease bowel motility; monitor for decrease bowel motility in postop patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Tolerance or drug dependence may result from extended use (withdrawal symptoms have been reported); abrupt discontinuation should be avoided. Tapering of dose at the time of discontinuation limits the risk of withdrawal symptoms. Concurrent use of mixed agonist/antagonist (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics may also precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229728\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229695\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9166&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the adverse/toxic effect of TraMADol. Specifically, both drugs have the potential to decrease the seizure threshold, possibly increasing the risk for seizures.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May enhance the analgesic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May diminish the analgesic effect of TraMADol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Monoamine Oxidase Inhibitor): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity if selegiline, rasagiline, or safinamide is combined with a serotonin modulator. Use of transdermal selegiline with serotonin modulators is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: Acetaminophen may increase the serum concentration of Busulfan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: TraMADol may enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Opioid Analgesics. Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of TraMADol. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of TraMADol. CYP2D6 Inhibitors (Strong) may increase the serum concentration of TraMADol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of TraMADol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Opioid Analgesics may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyraPONE: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moclobemide: TraMADol may enhance the serotonergic effect of Moclobemide. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: May diminish the therapeutic effect of Opioid Analgesics. Management: Avoid the concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics. If combined, larger doses of opioid analgesics will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids.  See full drug interaction monograph for detailed recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Analgesics. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylephrine (Systemic): Acetaminophen may increase the serum concentration of Phenylephrine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Opioid Analgesics may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease serum concentrations of the active metabolite(s) of TraMADol. Ritonavir may increase the serum concentration of TraMADol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: May enhance the bradycardic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with daily acetaminophen doses exceeding 1.3 or 2 g/day for multiple consecutive days. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): TraMADol may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229714\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food may delay time to peak plasma levels, however, the extent of absorption is not affected. Management: Administer without regard to meals. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229709\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Acetaminophen and tramadol cross the placenta. Use is not recommended prior to or during labor and delivery.<b> [US Boxed Warning]: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</b> Refer to individual monographs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229710\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Acetaminophen and tramadol are present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer. Refer to individual monographs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229700\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Pain relief, respiratory and mental status, blood pressure, heart rate; signs of tolerance, addiction, abuse, misuse, or suicidal ideation; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229690\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: Although not fully elucidated, the analgesic effects are believed to be due to activation of descending serotonergic inhibitory pathways in the CNS. Interactions with other nociceptive systems may be involved as well (Smith 2009). Antipyresis is produced from inhibition of the hypothalamic heat-regulating center.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tramadol: Binds to &mu;-opiate receptors in the CNS causing inhibition of ascending pain pathways, altering the perception of and response to pain; also inhibits the reuptake of norepinephrine and serotonin, which also modifies the ascending pain pathway</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229705\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229708\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tramadol-Acetaminophen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5-325 mg (100): $102.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ultracet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5-325 mg (100): $301.04</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1582163\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acetram (ID);</li>\n      <li>Acetram-Semi (KR);</li>\n      <li>Algodol (LB);</li>\n      <li>Analgan Tram (EC);</li>\n      <li>Analtram (ID);</li>\n      <li>Bantuan (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Beartra (KR);</li>\n      <li>Calmex (PY);</li>\n      <li>Cetadol (PH);</li>\n      <li>Cetamadole (KR);</li>\n      <li>Cetodol (PH);</li>\n      <li>Cetra (PH);</li>\n      <li>Clocinol (LV);</li>\n      <li>Dolantag (EC, PE);</li>\n      <li>Dolcet (PH);</li>\n      <li>Dologesic (PH);</li>\n      <li>Doltramcet (KR);</li>\n      <li>Dotramol (ID);</li>\n      <li>Duocetz (TH);</li>\n      <li>Duodyne (KR);</li>\n      <li>Fapdol (BD);</li>\n      <li>Fastdol (BD);</li>\n      <li>Fastfen (CO);</li>\n      <li>Hantracet (KR);</li>\n      <li>Hycephen (HK);</li>\n      <li>Ixprim (FR, IE);</li>\n      <li>Malcet (LB);</li>\n      <li>Metagesic (EC);</li>\n      <li>Nalsarac (VN);</li>\n      <li>Neutracet (KR);</li>\n      <li>Nutram (PH);</li>\n      <li>Paratram (BR);</li>\n      <li>Pradol (PH);</li>\n      <li>Rapicet (KR);</li>\n      <li>Sincronik (ID);</li>\n      <li>Sinergic (ID);</li>\n      <li>Supercet (PE);</li>\n      <li>Suprafen (KR);</li>\n      <li>Tafitram (CR, DO, GT, HN, SV);</li>\n      <li>Tracan (KR);</li>\n      <li>Traceton (TW);</li>\n      <li>Trafitram (NI, PA);</li>\n      <li>Tralic TP (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Tramacet (BB, BM, BS, BZ, CO, CR, DO, GB, GT, GY, HN, JM, MX, NI, PA, PR, SR, SV, TT, ZW);</li>\n      <li>Tramiphen (KR);</li>\n      <li>Ultracet (BR, CN, HK, ID, KR, MY, SG, TH, TW, VE);</li>\n      <li>Ultramac Semi (KR);</li>\n      <li>Utracet (BD);</li>\n      <li>Xcel Max (BD);</li>\n      <li>Zafin (EC, PY);</li>\n      <li>Zaldiar (AE, AT, BE, CH, CL, CO, CR, CZ, DE, DO, EE, ES, FR, GT, HN, HR, HU, ID, IL, KW, LB, LU, LV, MT, MX, NI, NL, PA, PE, PL, RO, RU, SA, SI, SK, SV, VE);</li>\n      <li>Zultracet (PK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Pain Society, <i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>, 6th ed, Glenview, IL: American Pain Society, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antlitz AM, Mead JA Jr, and Tolentino MA, &quot;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&quot; <i>Curr Ther Res Clin Exp</i>, 1968, 10(10):501-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/4971464/pubmed\" target=\"_blank\" id=\"4971464\">4971464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bagheri H, Bernhard NB, and Montastruc JL, &quot;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&quot; <i>Ann Pharmacother</i>, 1999, 33(4):506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/10332548/pubmed\" target=\"_blank\" id=\"10332548\">10332548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bartle WR and Blakely JA, &quot;Potentiation of Warfarin Anticoagulation by Acetaminophen,&quot; <i>JAMA</i>, 1991, 265(10):1260.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/1995971/pubmed\" target=\"_blank\" id=\"1995971\">1995971</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boeijinga JJ, Boerstra EE, Ris P, et al, &quot;Interaction Between Paracetamol and Coumarin Anticoagulants,&quot; <i>Lancet</i>, 1982, 1(8270):506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/6121161/pubmed\" target=\"_blank\" id=\"6121161\">6121161</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi: 0.1016/j.amjmed.2012.12.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/23414717/pubmed\" target=\"_blank\" id=\"23414717\">23414717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain&mdash;United States, 2016. <i>MMWR Recomm Rep</i>. 2016;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/26987082/pubmed\" target=\"_blank\" id=\"26987082\">26987082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fournier JP, Azoulay L, Yin H, et al. Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain. <i>JAMA Intern Med</i>. 2015;175(2):186-193. doi: 10.1001/jamainternmed.2014.6512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/25485799/pubmed\" target=\"_blank\" id=\"25485799\">25485799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fricke JR Jr, Hewitt DJ, Jordan DM, et al, &quot;A Double-Blind Placebo-Controlled Comparison of Tramadol/Acetaminophen and Tramadol in Patients With Postoperative Dental Pain,&quot; <i>Pain</i>, 2004, 109(3):250-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/15157685 /pubmed\" target=\"_blank\" id=\"15157685 \">15157685 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fricke JR Jr, Karim R, Jordan D, et al, &quot;A Double-Blind, Single-Dose Comparison of the Analgesic Efficacy of Tramadol/Acetaminophen Combination Tablets, Hydrocodone/Acetaminophen Combination Tablets, and Placebo After Oral Surgery,&quot; <i>Clin Ther</i>, 2002, 24(6):953-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/12117085 /pubmed\" target=\"_blank\" id=\"12117085 \">12117085 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &quot;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&quot; <i>J Thromb Haemost</i>, 2003, 1(4):714-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/12871405/pubmed\" target=\"_blank\" id=\"12871405\">12871405</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &quot;Warfarin and Acetaminophen Interaction,&quot; <i>Pharmacotherapy</i>, 2003, 23(1):109-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/12523469/pubmed\" target=\"_blank\" id=\"12523469\">12523469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hylek EM, Heiman H, Skates SJ, et al, &quot;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&quot; <i>JAMA</i>, 1998, 279(9):657-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/9496982/pubmed\" target=\"_blank\" id=\"9496982\">9496982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kwan D, Bartle WR, and Walker SE, &quot;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&quot; <i>Clin Pharmacol Ther</i>, 1995, 57:212.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Medve RA, Wang J, and Karim R, &quot;Tramadol and Acetaminophen Tablets for Dental Pain,&quot; <i>Anesth Prog</i>, 2001, 48(3):79-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/11724223 /pubmed\" target=\"_blank\" id=\"11724223 \">11724223 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin RN, Mentzer RL, and Budzynski AZ, &quot;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&quot; <i>Clin Res</i>, 1984, 32:698a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith AB, Ravikumar TS, Kamin M, et al, &quot;Combination Tramadol Plus Acetaminophen for Postsurgical Pain,' <i>Am J Surg</i>, 2004, 187(4):521-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/15041504 /pubmed\" target=\"_blank\" id=\"15041504 \">15041504 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith HS. Potential analgesic mechanisms of acetaminophen. <i>Pain Physician</i>. 2009;12(1):269-280.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/19165309/pubmed\" target=\"_blank\" id=\"19165309\">19165309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tramacet (acetaminophen and tramadol hydrochloride) [product monograph]. Toronto, Ontario: Janssen Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ultracet (tramadol hydrochloride and acetaminophen) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Bemt PM, Geven LM, Kuitert NA, et al, &quot;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&quot; <i>Pharm World Sci</i>, 2002, 24(5):201-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/12426965/pubmed\" target=\"_blank\" id=\"12426965\">12426965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &quot;NSAIDS and Cardiovascular Effects, Celecoxib for Dental Pain, and a New Analgesic - Tramadol with Acetaminophen,&quot; <i>Gen Dent</i>, 2002, 50(3):218-222.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetaminophen-paracetamol-and-tramadol-drug-information/abstract-text/12116507 /pubmed\" target=\"_blank\" id=\"12116507 \">12116507 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9166 Version 196.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F46307072\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F13114310\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F229717\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F1582162\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F229734\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F229719\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F229720\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F229721\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F229722\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F229702\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F229687\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F48842545\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F25708104\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F49627716\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F229703\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5118567\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F229693\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F229706\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F229691\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F229728\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F229695\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F229714\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F229709\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F229710\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F229700\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F229690\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F229705\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F229708\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F1582163\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9166|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=acetaminophen-paracetamol-and-tramadol-patient-drug-information\" class=\"drug drug_patient\">Acetaminophen (paracetamol) and tramadol: Patient drug information</a></li></ul></div></div>","javascript":null}